← Back to Clinical Trials
Recruiting NCT06554197

NCT06554197 Evaluation of CMV/EBV-CMI in Haploid HSCT

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06554197
Status Recruiting
Phase
Sponsor The First Affiliated Hospital of Soochow University
Condition Hematopoietic Stem Cell Transplantation
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2024-08-13
Primary Completion 2025-07-31

Eligibility & Interventions

Sex All sexes
Min Age 16 Years
Max Age 60 Years
Study Type OBSERVATIONAL
Interventions
CMV/EBV-CMI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 60 participants in total. It began in 2024-08-13 with a primary completion date of 2025-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid hematopoietic stem cell transplantation(haplo-HSCT) .

Eligibility Criteria

Inclusion Criteria: 1. All patients were diagnosed with hemopathy. 2. All patients should have the indication of Haploidentical hematopoietic stem cell transplant and receive the prophylaxis for cytomegalovirus. 3. All patients should sign an informed consent document indicating that they understand the purpose of and procedures required for the study and be willing to participate in the study. Exclusion Criteria: Patients with any conditions not suitable for the trial (investigators' decision).

Contact & Investigator

Central Contact

Feng Chen, PhD

✉ 13584861215@163.com

📞 13584861215

Frequently Asked Questions

Who can join the NCT06554197 clinical trial?

This trial is open to participants of all sexes, aged 16 Years or older, up to 60 Years, studying Hematopoietic Stem Cell Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06554197 currently recruiting?

Yes, NCT06554197 is actively recruiting participants. Contact the research team at 13584861215@163.com for enrollment information.

Where is the NCT06554197 trial being conducted?

This trial is being conducted at Suzhou, China.

Who is sponsoring the NCT06554197 clinical trial?

NCT06554197 is sponsored by The First Affiliated Hospital of Soochow University. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology